OPKO Health - OPK Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OPKO Health in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" OPK shares.
View OPK analyst ratings or view top-rated stocks.

2 brokerages have issued 12-month price targets for OPKO Health's stock. Their OPK share price forecasts range from $4.00 to $4.00. On average, they expect the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 181.7% from the stock's current price.
View analysts price targets for OPK or view top-rated stocks among Wall Street analysts.

OPKO Health's stock was trading at $4.81 at the beginning of the year. Since then, OPK stock has decreased by 70.5% and is now trading at $1.42.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our OPK earnings forecast.

OPKO Health, Inc. (NASDAQ:OPK) announced its quarterly earnings results on Thursday, October, 28th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.05. The biotechnology company had revenue of $385.80 million for the quarter, compared to analysts' expectations of $302.27 million. OPKO Health had a negative trailing twelve-month return on equity of 14.79% and a negative net margin of 25.98%. The firm's revenue was down 9.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.04 earnings per share.

21 employees have rated OPKO Health Chief Executive Officer Philip Frost on Glassdoor.com. Philip Frost has an approval rating of 16% among the company's employees. This puts Philip Frost in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other OPKO Health investors own include TherapeuticsMD (TXMD), Micron Technology (MU), NVIDIA (NVDA), bluebird bio (BLUE), Gilead Sciences (GILD), Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Advanced Micro Devices (AMD) and AT&T (T).

OPKO Health trades on the NASDAQ under the ticker symbol "OPK."

OPKO Health's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.21%), BlackRock Inc. (4.47%), Dimensional Fund Advisors LP (1.40%), State Street Corp (1.34%), Oracle Investment Management Inc. (0.66%) and Two Sigma Investments LP (0.37%). Insiders that own company stock include Anthony J Japour, Elias A Zerhouni, Gary J Nabel, Jon R Cohen, Phillip Md Et Al Frost, Robert J Shovlin and Steven D Rubin.
View institutional ownership trends.

Shares of OPK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OPK stock can currently be purchased for approximately $1.42.

OPKO Health (NASDAQ:OPK) has a market capitalization of $1.10 billion and generates $1.77 billion in revenue each year. The biotechnology company earns $-30,140,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis.

The company employs 5,767 workers across the globe.

OPKO Health's mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The official website for the company is www.opko.com. The biotechnology company can be reached via phone at (305) 575-4100, via email at mmiller@lhai.com, or via fax at 305-575-6015.